Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Centella Asiatica in Elderly
NCT03929250Phase 1Completed
- Sponsor
- Oregon Health & Science University
- Start
- Jul 2019
- Primary completion
- Nov 2019
- Modality
- PE (Plant extract)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of centella asiatica in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Oregon Health & Science University. Primary endpoints: Maximum Human Plasma Concentration of Bioactives at 12 hours, Total Plasma Concentration Over Time (Area Under the Curve) at 12 hours and 2 more. Started Jul 2019; status: completed.
02
Drugs
centella asiatica
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03929250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929250.